These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16469749)

  • 21. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs).
    Lafleur MA; Handsley MM; Knäuper V; Murphy G; Edwards DR
    J Cell Sci; 2002 Sep; 115(Pt 17):3427-38. PubMed ID: 12154073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
    Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
    J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation.
    Hernandez-Barrantes S; Toth M; Bernardo MM; Yurkova M; Gervasi DC; Raz Y; Sang QA; Fridman R
    J Biol Chem; 2000 Apr; 275(16):12080-9. PubMed ID: 10766841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain.
    Kai HS; Butler GS; Morrison CJ; King AE; Pelman GR; Overall CM
    J Biol Chem; 2002 Dec; 277(50):48696-707. PubMed ID: 12374789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP.
    Hernandez-Barrantes S; Shimura Y; Soloway PD; Sang QA; Fridman R
    Biochem Biophys Res Commun; 2001 Feb; 281(1):126-30. PubMed ID: 11178970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of matrix metalloproteinase (TIMP)-2 during bovine placentation and at term with or without placental retention.
    Dilly M; Hambruch N; Shenavai S; Schuler G; Froehlich R; Haeger JD; Ozalp GR; Pfarrer C
    Theriogenology; 2011 Apr; 75(6):1104-14. PubMed ID: 21247626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expression and localization of selected matrix metalloproteinases (MMP-2, -7 and -9) and their tissue inhibitors (TIMP-2 and -3) in follicular cysts of sows.
    Grzesiak M; Kaminska K; Knapczyk-Stwora K; Hrabia A
    Theriogenology; 2022 Jun; 185():109-120. PubMed ID: 35395587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of matrix metalloproteinases (MMP-2, -7, -9) and their tissue inhibitors (TIMP-2, -3) in the regression of chicken postovulatory follicles.
    Hrabia A; Socha JK; Sechman A
    Gen Comp Endocrinol; 2018 May; 260():32-40. PubMed ID: 29438675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
    Lu KV; Jong KA; Rajasekaran AK; Cloughesy TF; Mischel PS
    Lab Invest; 2004 Jan; 84(1):8-20. PubMed ID: 14631378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2.
    Elliot S; Catanuto P; Stetler-Stevenson W; Cousins SW
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1696-702. PubMed ID: 16565411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines.
    Maquoi E; Frankenne F; Baramova E; Munaut C; Sounni NE; Remacle A; Noël A; Murphy G; Foidart JM
    J Biol Chem; 2000 Apr; 275(15):11368-78. PubMed ID: 10753951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts.
    Ottino P; He J; Axelrad TW; Bazan HE
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):487-96. PubMed ID: 15671273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line.
    Harayama T; Ohuchi E; Aoki T; Sato H; Seiki M; Okada Y
    Jpn J Cancer Res; 1999 Sep; 90(9):942-50. PubMed ID: 10551322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface.
    Itoh Y; Ito A; Iwata K; Tanzawa K; Mori Y; Nagase H
    J Biol Chem; 1998 Sep; 273(38):24360-7. PubMed ID: 9733724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of a latent soluble form of membrane type 1 matrix metalloprotease bound with tissue inhibitor of matrix metalloproteinases-2 in periprosthetic tissues and fluids from loose arthroplasty endoprostheses.
    Niarakis A; Giannopoulou E; Ravazoula P; Panagiotopoulos E; Zarkadis IK; Aletras AJ
    FEBS J; 2013 Dec; 280(24):6541-55. PubMed ID: 24112707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels.
    Kudo T; Takino T; Miyamori H; Thompson EW; Sato H
    Cancer Sci; 2007 Apr; 98(4):563-8. PubMed ID: 17425593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of matrix metalloproteases (MMP-2, MT1 -MMP) and their tissue inhibitor (TIMP-2) by rat sertoli cells in culture: implications for spermatogenesis.
    Slongo ML; Zampieri M; Onisto M
    Biol Chem; 2002 Jan; 383(1):235-9. PubMed ID: 11928819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.
    Chernov AV; Sounni NE; Remacle AG; Strongin AY
    J Biol Chem; 2009 May; 284(19):12727-34. PubMed ID: 19286653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.